Eva Herrmann
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmanith T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology (Oxford) 2021; 60:5318-5328.
Jan 3, 2021Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Jan 3, 2021Rheumatology (Oxford) 2021; 60:5318-5328
Behrens Frank, Wassenberg Siegfried, Tony Hans-Peter, Rubbert-Roth Andrea, Müller-Ladner Ulf, Lehn Annette, Krueger Klaus, Kellner Herbert, Herrmann Eva, Feist Eugen, Burmester Gerd R, Backhaus Marina, Aringer Martin, Alten Rieke, Rossmanith Tanja, Koehm Michaela, Burkhardt Harald
Bolus timing in high-pitch CT angiography of the aorta
Beeres M, Vogl T, Jacobi V, Lee C, Gruber-Rouh T, Herrmann E, Bodelle B, Al-Butmeh F, Kerl M, Schulz B, Loch M, Bauer R. Bolus timing in high-pitch CT angiography of the aorta. Eur J Radiol 2013; 82:1028-33.
Jan 31, 2013Bolus timing in high-pitch CT angiography of the aorta
Jan 31, 2013Eur J Radiol 2013; 82:1028-33
Beeres Martin, Vogl Thomas J, Jacobi Volkmar, Lee Clara, Gruber-Rouh Tatjana, Herrmann Eva, Bodelle Boris, Al-Butmeh Firas, Kerl Matthias, Schulz Boris, Loch Matthias, Bauer Ralf
High-pitch dual-source CT angiography of the whole aorta without ECG synchronisation: initial experience
Beeres M, Jacobi V, Vogl T, Zangos S, Bodelle B, Siebenhandl P, Lee C, Gruber-Rouh T, Kerl J, Herrmann E, Mastragelopoulos A, Schell B, Bauer R. High-pitch dual-source CT angiography of the whole aorta without ECG synchronisation: initial experience. Eur Radiol 2011; 22:129-37.
Sep 14, 2011High-pitch dual-source CT angiography of the whole aorta without ECG synchronisation: initial experience
Sep 14, 2011Eur Radiol 2011; 22:129-37
Beeres Martin, Jacobi Volkmar, Vogl Thomas J, Zangos Stephan, Bodelle Boris, Siebenhandl Petra, Lee Clara, Gruber-Rouh Tatjana, Kerl Josef Matthias, Herrmann Eva, Mastragelopoulos Aristidis, Schell Boris, Bauer Ralf
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. European journal of gastroenterology & hepatology 2007; 19:639-46.
Aug 1, 2007Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
Aug 1, 2007European journal of gastroenterology & hepatology 2007; 19:639-46
Kronenberger Bernd, Hopf Uwe, Pape Gerd R, Wursthorn Karsten, Nasser Samer, Goeser Tobias, Spengler Ulrich, Buggisch Peter, Gerlach Tilman, Hinrichsen Holger, Herrmann Eva, Berg Thomas, Zeuzem Stefan
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
Aug 1, 2005Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
Aug 1, 2005Gastroenterology 2005; 129:522-7
von Wagner Michael, Herrmann Eva, Häussinger Dieter, Bernsmeier Christine, Bergk Alexandra, Heintges Tobias, Rasenack Jens, Hinrichsen Holger, Berg Thomas, Huber Miriam, Zeuzem Stefan
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology (Baltimore, Md.) 2003; 37:1359-67.
Jun 1, 2003Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
Jun 1, 2003Hepatology (Baltimore, Md.) 2003; 37:1359-67
Berg Thomas, Hopf Uwe, Pape Gerd R, Wursthorn Karsten, Nasser Samer, Goeser Tobias, Spengler Ulrich, Herrmann Eva, Buggisch Peter, Gerlach Tilman, Hinrichsen Holger, Kronenberger Bernd, Zeuzem Stefan
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (Baltimore, Md.) 2003; 37:600-9.
Mar 1, 2003Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
Mar 1, 2003Hepatology (Baltimore, Md.) 2003; 37:600-9
Berg Thomas, Sarrazin Christoph, Herrmann Eva, Hinrichsen Holger, Gerlach Tilman, Zachoval Reinhart, Wiedenmann Bertram, Hopf Uwe, Zeuzem Stefan